Adalta Ltd

ASX:1AD ISIN:AU0000001AD2

AdAlta Limited (ASX:1AD) is an Australian-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.  
 

News

Regeneus Ltd (ASX:RGS) Appoints International Directors for Global Growth

🕔4/29/2019 8:48:54 AM 5220

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors, effective 29 April 2019 as independent, Non-Executive Directors.

Read Full Article
###

2,150 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 5) (Last 30 Days: 21) (Since Published: 2150) 

Company Data

    Headquarters
  • 15/2 Park Drive
    Bundoora Victoria 3083
    Australia
  • Telephone
  • +61-3-9479-5159 
  • Principal Sector
  • Drugs & OTC 
  • Principal Industry
  • Medical Products 
  • Homepage
  • www.adalta.com.au
  • E:
  • s.cobb@adalta.com.au

More News Results

  • 2024/12/05: Change of Director's Interest Notice (TO)*
  • 2024/12/05: Notification regarding unquoted securities - 1AD*
  • 2024/12/02: Presentation at ASCEPT, APFP & APSA Joint Congress*
  • 2024/11/21: Investor Presentation*
  • 2024/11/21: Final Director's Interest Notice (RP)*
  • 2024/11/21: Initial Director's Interest Notice X 2 (MB & IR)*
  • 2024/11/20: Results of Meeting*
  • 2024/11/20: Chair address and CEO presentation to AGM*
  • 2024/11/18: Board changes*
  • 2024/11/05: Change in substantial holding*
*refer to company website